Dr. David Reese is the senior vice president of Translational Sciences at Amgen, where he’s responsible for Medical Sciences, Comparative Biology and Safety Sciences, and Pharmacokinetics and Drug Metabolism. At Amgen, he was instrumental in the development of T-Vec (IMLYGIC), an FDA-approved oncolytic virus immunotherapy that uses a modified herpes virus to treat melanoma. Dr. Reese is a member of CRI’s Cancer Immunotherapy Consortium (CIC) Steering Committee.
[T-Vec] is a first-in-class oncolytic virus that is on the leading edge of an explosion of these oncolytic viruses. The next wave in immuno-oncology will be combination approaches, and we have early data suggesting that combinations of [T-Vec] with checkpoint inhibitors will be of interest.
Let's spread the word about Immunotherapy! Click to share this page with your community.